BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abbott Laboratories (ABT) Doubled Niaspan U.S. Sales Before Trials Cut Use


6/11/2013 7:31:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Abbott Laboratories (ABT) aggressively promoted its Niaspan cholesterol treatment, almost tripling U.S. use of the medication, in the seven-year period before studies in 2011 found the drug ineffective, a study found. From 2002 to 2009, niacin and its brand-name counterpart Niaspan, now sold by Abbott’s spinoff company AbbVie Inc. (ABBV), rose 191 percent in the U.S., to 696,000 prescriptions a month. A combination of assertive marketing and stronger medical guidelines for reducing cholesterol levels drove that increase, according to research published today in the journal JAMA Internal Medicine. Abbott and AbbVie boosted Niaspan prices to almost completely offset prescription numbers that fell starting in 2011, according to sales data compiled last month by Bloomberg. Two studies released then and in 2012 found the medicine didn’t help patients and may have hurt them. Price increases helped AbbVie hold on to revenue from the drug even as evidence against it mounted.

Help employers find you! Check out all the jobs and post your resume.


Read at Bloomberg

Bloomberg
Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES